Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Currently used second-line agents: do they control the disease course?

L B van de Putte1, P L van Riel

  • 1Department of Rheumatology, University Hospital of Nijmegen, The Netherlands.

Clinical and Experimental Rheumatology
|May 1, 1997
PubMed
Summary

Rheumatoid arthritis treatment now uses second-line agents (SLAs) earlier to prevent joint damage. Effective SLA combinations show promise over monotherapy, potentially slowing disease progression.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

European genetic study on rheumatoid arthritis: is there a linkage of the interleukin-1 (IL-1), IL-10 or IL-4 genes to RA?

Clinical and experimental rheumatology·2002
Same author

Role of activatory Fc gamma RI and Fc gamma RIII and inhibitory Fc gamma RII in inflammation and cartilage destruction during experimental antigen-induced arthritis.

The American journal of pathology·2001
Same author

The C677T mutation in the methylenetetrahydrofolate reductase gene: a genetic risk factor for methotrexate-related elevation of liver enzymes in rheumatoid arthritis patients.

Arthritis and rheumatism·2001
Same author

[Treatment of rheumatoid arthritis by inhibition of tumor necrosis factor with infliximab or etanercept].

Nederlands tijdschrift voor geneeskunde·2001
Same author

Treatment of active rheumatoid arthritis with leflunomide: two year follow up of a double blind, placebo controlled trial versus sulfasalazine.

Annals of the rheumatic diseases·2001
Same author

Prevention of symptomatic thrombosis with short term (low molecular weight) heparin in patients with rheumatoid arthritis after hip or knee replacement.

Annals of the rheumatic diseases·2001

Area of Science:

  • Rheumatology
  • Immunology
  • Pharmacology

Background:

  • Rheumatoid arthritis (RA) joint damage begins early in the disease course.
  • Treatment paradigms for RA have evolved, emphasizing early intervention.
  • The availability of effective second-line agents (SLAs) has increased.

Purpose of the Study:

  • To review recent changes in rheumatoid arthritis treatment with second-line agents.
  • To highlight the impact of early intervention and novel SLAs on disease management.
  • To discuss the efficacy of SLA combinations versus monotherapy.

Main Methods:

  • Review of recent clinical data and studies on rheumatoid arthritis treatment.
  • Analysis of treatment trends and drug survival rates for second-line agents.

Related Experiment Videos

  • Evaluation of evidence regarding radiographic progression and combination therapies.

    • Main Results:

    • Patients with rheumatoid arthritis are increasingly treated earlier with second-line agents.
    • Newer SLAs offer faster action and improved drug survival.
    • Short-term data suggest effective SLA treatment slows radiographic progression.
    • Some SLA combinations demonstrate superior efficacy compared to monotherapy.

    Conclusions:

    • Early treatment with second-line agents is crucial for managing rheumatoid arthritis.
    • The evolving landscape of SLAs offers improved therapeutic options for RA patients.
    • Combination therapy with SLAs may represent a more effective treatment strategy.